Matinas BioPharma Holdings (MTNB) Long-Term Deferred Tax (2022)
Matinas BioPharma Holdings (MTNB) posted quarterly Long-Term Deferred Tax of $1.7 million for Q3 2022, little changed quarter-over-quarter from $1.7 million in Q2 2022.
Matinas BioPharma Holdings (MTNB) Long-Term Deferred Tax (2022) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Long-Term Deferred Tax for 1 consecutive years, with $1.7 million the latest figure, recorded in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.60 Bn | 130.75 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.93 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.06 Bn | 59.88 Bn | 1.37 Bn |
| 4 | Moderna | 56.22 Bn | 51.08 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.65 Bn | 28.34 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - |
| 10 | Matinas BioPharma Holdings | 1.24 Mn | 431,160.46 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 1.73 Mn |
| Jun 30, 2022 | 1.73 Mn |